National Bioproducts Institute
NBI is a private, non-profit pharmaceutical manufacturer dedicated to improving the quality of life of patients globally by providing safe, cost-effective, and high-quality medicinal products, including plasma-derived therapies, diagnostic products, and biotechnological innovations. With a history dating back to the 1960s, NBI operates Africa's only specialized manufacturing facility for plasma-derived medicinal products, adhering to international quality standards and regulatory compliance. The company’s mission is to meet patient needs through the production and distribution of therapeutic proteins and diagnostic products within Africa and globally, emphasizing innovation, quality, and stakeholder engagement.
Industries
Nr. of Employees
medium (51-250)
National Bioproducts Institute
10 Eden Road, Pinetown, 3610, South Africa. Private Bag X9043, Pinetown, 3600, South Africa.
Products
Therapeutic human plasma product
Plasma product for clinical use where plasma and/or clotting factors are required.
Human normal immunoglobulins (intramuscular and intravenous)
Intramuscular and intravenous immunoglobulin formulations for replacement therapy and immunomodulation.
Human albumin solutions
Albumin formulations recommended for management of low blood volume, burns, hypoalbuminaemia and dialysis/plasma exchange support.
Human anti-D immunoglobulin
Immunoglobulin product for prevention of haemolytic disease of the newborn and management of Rh-incompatible exposures.
Human hepatitis B, rabies, tetanus and varicella-zoster immunoglobulins
Post-exposure and prophylactic immunoglobulin products containing antibodies specific to hepatitis B, rabies, tetanus and varicella-zoster.
Coagulation factor products (factor VIII concentrate and factor IX complex)
Plasma-derived coagulation factor concentrates for treatment of haemophilia A and B and related bleeding disorders.
Therapeutic human plasma product
Plasma product for clinical use where plasma and/or clotting factors are required.
Human normal immunoglobulins (intramuscular and intravenous)
Intramuscular and intravenous immunoglobulin formulations for replacement therapy and immunomodulation.
Human albumin solutions
Albumin formulations recommended for management of low blood volume, burns, hypoalbuminaemia and dialysis/plasma exchange support.
Human anti-D immunoglobulin
Immunoglobulin product for prevention of haemolytic disease of the newborn and management of Rh-incompatible exposures.
Human hepatitis B, rabies, tetanus and varicella-zoster immunoglobulins
Post-exposure and prophylactic immunoglobulin products containing antibodies specific to hepatitis B, rabies, tetanus and varicella-zoster.
Coagulation factor products (factor VIII concentrate and factor IX complex)
Plasma-derived coagulation factor concentrates for treatment of haemophilia A and B and related bleeding disorders.
Services
On-site production of therapeutic plasma-derived products using fractionation, refining, formulation and sterile filling for clinical use.
Development and manufacture of monoclonal antibodies, ELISA kits and point-of-care diagnostic kits for infectious disease diagnostics.
Laboratory services for product and process development of biologics and plasma-derived products, including scale-up support.
On-site production of therapeutic plasma-derived products using fractionation, refining, formulation and sterile filling for clinical use.
Development and manufacture of monoclonal antibodies, ELISA kits and point-of-care diagnostic kits for infectious disease diagnostics.
Laboratory services for product and process development of biologics and plasma-derived products, including scale-up support.
Expertise Areas
- Plasma-derived medicinal product manufacturing
- Monoclonal antibody development and production
- Diagnostic reagent and point-of-care kit manufacturing
- Protein expression and purification
Key Technologies
- Cold ethanol fractionation
- Monoclonal antibody production
- Recombinant protein expression
- Cell culture
News & Updates
On 24/01/2025, NBI announced the appointment of Maishibe Ntlhane as the new Chief Executive Officer, highlighting leadership in strategic growth.
On 04/11/2024, NBI unveiled a new logo and celebrated three decades of pioneering healthcare solutions.
On 24/10/2023, NBI was featured in Africa Outlook Magazine, showcasing its contributions to healthcare in Africa.
On 24/10/2022, NBI announced a strategic partnership with Imperial's Market Access Healthcare business to expand in Africa.
Biolayer interferometry predicts ELISA performance
Research on predicting ELISA performance of monoclonal antibody pairs for Plasmodium falciparum.
Production of monoclonal antibodies for malaria diagnosis
Development and characterization of monoclonal antibodies targeting Plasmodium falciparum biomarkers.
On 24/01/2025, NBI announced the appointment of Maishibe Ntlhane as the new Chief Executive Officer, highlighting leadership in strategic growth.
On 04/11/2024, NBI unveiled a new logo and celebrated three decades of pioneering healthcare solutions.
On 24/10/2023, NBI was featured in Africa Outlook Magazine, showcasing its contributions to healthcare in Africa.
On 24/10/2022, NBI announced a strategic partnership with Imperial's Market Access Healthcare business to expand in Africa.
Biolayer interferometry predicts ELISA performance
Research on predicting ELISA performance of monoclonal antibody pairs for Plasmodium falciparum.
Production of monoclonal antibodies for malaria diagnosis
Development and characterization of monoclonal antibodies targeting Plasmodium falciparum biomarkers.